The Claim
PCSK9 promotes the degradation of major histocompatibility complex class I (MHCI) on cancer cells, leading to reduced tumor antigen presentation to cytotoxic T cells and suppression of anti-tumor immunity; inhibition of PCSK9 increases cell surface MHCI expression and enhances CD8+ T cell infiltration in mouse tumor models, resulting in suppressed tumor growth through a mechanism independent of LDLR.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Blocking a protein called PCSK9 helps the immune system better recognize and attack cancer cells in mice, slowing tumor growth — and it works in a way that's not related to cholesterol.
See the scientific wording
PCSK9 promotes degradation of major histocompatibility complex class I (MHCI) on cancer cells, which reduces tumor antigen presentation to cytotoxic T cells and suppresses anti-tumor immunity; inhibition of PCSK9 increases cell surface MHCI levels and enhances CD8+ T cell infiltration in mouse tumor models, leading to suppressed tumor growth in a LDLR-independent manner.
What the research says
1 studyStudy: Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
The study says that blocking PCSK9 helps the immune system see cancer cells better and slow their growth, which matches the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.